Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination
Information source: Centre d'Appui à la lutte contre la Maladie
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Parasitic Diseases; Bacterial Diseases
Intervention: triple co administration at once of the combination of Albendazole + ivermectin + azithromycin (Drug)
Phase: N/A
Status: Completed
Sponsored by: Centre d'Appui à la lutte contre la Maladie Official(s) and/or principal investigator(s):
Samba O Sow, MD, MPH, Principal Investigator, Affiliation: CNAM, Mali
Summary
The purpose of this study is to determine whether the triple co administration of
albendazole, ivermectin and azithromycine is as safe as the current treatment scheme that
consists to treat with albendazole plus ivermectin together and a week later to treat with
azithromycin in areas co endemic for lymphatic filariasis and trachoma.
Clinical Details
Official title: A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali
Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Establish the incidence of adverse events associated with the mass triple drug administration
Secondary outcome: Establish the incidence of serious adverse events associated with the mass triple drug administration
Detailed description:
Infectious diseases such as trachoma and lymphatic filariasis are public health problems in
regions of Africa and Asia. Elimination programs exist for the two diseases, and their
treatment by different groups of health workers is both costly and inefficient.
Thus, a study evaluating the safety and feasibility of an integrated mass treatment of
trachoma and lymphatic filariasis with azithromycin associated with albendazole and
ivermectin was instituted in 4 villages of the region of Sikasso in Mali (West Africa) co
endemic for lymphatic filariasis and trachoma.
It was an open label randomized clusters type on the assessment of the safety of the triple
co administration of azithromycin, ivermectin and albendazole (experimental regimen) as
compared to the administration of the co administration of albendazole plus ivermectin
followed by the that of azithromycin a week later (current standard recommended regimen)
within subjects of 5 to 65 years old, willing and able to swallow the study drugs.
Clinical evaluation of adverse events in all study participants was done on day 0, day 8,
and day 15 after the treatment.
Eligibility
Minimum age: 5 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Must have been residing in the village for at least three months;
- Must be 90 cm tall or more;
- Must be between 5 years and 65 years of age;
- Must not be pregnant;
- Must not be lactating.
Exclusion Criteria:
- Subjects under 5 years of age or less than 90 cm in height;
- Subjects over 65 years of age;
- Subjects who cannot swallow tablets;
- Subjects who are sick and bedridden;
- Pregnant women (clinical appreciation in the study);
- Lactating women;
- History of allergies to the drugs being studied (azithromycin, ivermectin,
albendazole).
Locations and Contacts
Centre National D'Appui a la lutte contre la Maladie, Bamako, Mali
Additional Information
Starting date: February 2010
Last updated: April 24, 2012
|
